In the rat pituitary gland the mechanism responsible for ER␣ regulation has not been fully elucidated. Using transient transfection assays in ␣T3-1 cells, a cell line of gonadotrope origin, we show that GnRH stimulates estrogen response element-containing promoters in an estrogen-independent manner. This effect was strictly ER and GnRH receptor dependent, as no activation of the reporter gene was observed in presence of the anti-estrogen ICI 182,780 or a GnRH antagonist. These data suggest that the GnRH-triggered signaling pathway results in 17␤-estradiol-independent trans-activation of the ER␣ in ␣T3-1 cells. Furthermore, an additive activation was achieved when cells were treated with both GnRH and 17␤-estradiol. In primary pituitary cells, GnRH alone (100 nM) did not cause a significant stimulation of reporter gene activity, presumingly due to the low amount of gonadotropes. Interestingly, the combination of 17␤-estradiol and GnRH resulted in a significant increase in ER␣ trans Most of the E2 responses are mediated through a specific intracellular ER. To date, two ERs (ER␣ and ER␤) encoded by two separate genes have been described (2, 3). These two receptors belong to the nuclear receptor superfamily of ligand-inducible transcription factors whose members, the steroid receptors, TRs, and RARs, regulate gene expression by interacting either in a DNA-protein manner with cognate DNA sequences called responsive elements (for reviews, see Refs. 4 and 5) or in a protein-protein manner with other transcriptional factors (6 -8).
In the rat pituitary gland the mechanism responsible for ER␣ regulation has not been fully elucidated. Using transient transfection assays in ␣T3-1 cells, a cell line of gonadotrope origin, we show that GnRH stimulates estrogen response element-containing promoters in an estrogen-independent manner. This effect was strictly ER and GnRH receptor dependent, as no activation of the reporter gene was observed in presence of the anti-estrogen ICI 182,780 or a GnRH antagonist. These data suggest that the GnRH-triggered signaling pathway results in 17␤-estradiol-independent trans-activation of the ER␣ in ␣T3-1 cells. Furthermore, an additive activation was achieved when cells were treated with both GnRH and 17␤-estradiol. In primary pituitary cells, GnRH alone (100 nM) did not cause a significant stimulation of reporter gene activity, presumingly due to the low amount of gonadotropes. Interestingly, the combination of 17␤-estradiol and GnRH resulted in a significant increase in ER␣ trans 
R EGULATION OF THE hypothalamic-pituitary-gonadal
axis involves a complex interplay of peptides and steroid hormones. The mechanisms of feedback regulation by sex steroids are complex and include effects at both hypothalamic and pituitary levels. Ovarian steroids, 17␤-estradiol (E2) and progesterone, exert positive and negative feedback controls at both the brain and the pituitary level (for review, see Ref. 1) . Most of the E2 responses are mediated through a specific intracellular ER. To date, two ERs (ER␣ and ER␤) encoded by two separate genes have been described (2, 3) . These two receptors belong to the nuclear receptor superfamily of ligand-inducible transcription factors whose members, the steroid receptors, TRs, and RARs, regulate gene expression by interacting either in a DNA-protein manner with cognate DNA sequences called responsive elements (for reviews, see Refs. 4 and 5) or in a protein-protein manner with other transcriptional factors (6 -8) .
GnRH, produced by neurons in the hypothalamus, plays a predominant role in gonadotropin regulation. Pulsatile release of GnRH is necessary for expression of the gonadotropin genes and for hormone secretion (for review, see Ref.
1). In gonadotrope cells, binding of GnRH to its seven-transmembrane G protein-coupled receptor (GnRH-R) initiates a concert of intracellular signaling pathways, including stimulation of calcium influx and activation of PLC, which leads to increased protein kinase activities (for review, see Refs. 9 -11). Although it is clear that GnRH is essential for gonadotropin gene expression, the transcription factors mediating the effects of GnRH-induced signals on transcription of gonadotropin genes remain unknown. The PKC/MAPK pathway activated by GnRH preferentially stimulates ␣-subunit gene transcription, probably by phosphorylation of the Ets family transcription factors (12) . Recent studies have identified several key factors involved in LH␤ gonadotropin gene transcriptional regulation: the nuclear receptor SF-1, the bicoid-related homeoprotein Ptxl (Pitxl), and the immediateearly egr-1 gene (13) .
In addition to the classical ligand-dependent activation, there is evidence for cross-coupling between intracellular steroid hormone receptors and membrane-bound signaling pathways (for review, see Refs. 14 and 15). Stimulation of numerous growth factor receptors and/or protein kinases leads to ligand-independent or synergistic increase in ER␣ trans-activation, presumingly by ER␣ phosphorylation (for review, see Refs. 14 -16). The possible importance of phosphorylation for ER␣ function was initially indicated by the finding that the neurotransmitter, dopamine, can activate ER␣ in the absence of ligand (17) . Other groups have since shown that heregulin (18) , insulin (19) , as well as cAMP (14, 20) , PKC (21) , and phorbol esters (22) can also activate ER␣. Moreover, Turgeon and Waring (23) have shown a GnRHdependent activation of rat PR in primary rat pituitary cells.
Whereas ER appears to play a critical role in the control of pituitary gland and gonadotropin regulation, the mechanisms responsible for pituitary ER regulation (for the gene as well as the protein) have not been fully elucidated. In the adult anterior pituitary gland, estrogen-binding sites are localized within gonadotrope, lactotrope, somatotrope, and thyrotrope cells, with the highest amounts in gonadotrope cells. More recently, several groups (24 -28) have demonstrated that ER␣ is the predominant species in the adult rat pituitary. Concerning the presence of ER␤ mRNA and protein in pituitary cells, conflicting data have been published (24 -28) . Nevertheless, it seems that the amount of ER␤ pro-tein in the pituitary would be extremely low (28) . It is well established that the level of ER␣ expression is closely correlated to the magnitude of the ER-mediated response. Among the factors that may alter the level of ER␣ expression, estrogens themselves appear to be the primary negative or positive regulators in many E2-responsive tissues (reviewed in Ref. 29) . On the other hand, there is evidence that the pituitary ER␣ expression level is dependent on trophic factors from the hypothalamus, because median eminence lesions result in a reduction of the receptor in this gland (30) . Moreover, Singh and Muldoon (31) showed that exposure to GnRH significantly increased nuclear E2 binding, both in vivo and in vitro, and suggested a direct effect of GnRH on pituitary ER␣. Cocultures of pituitary cells with hypothalamic explants for 16 h allowed us to confirm the release of factors able to modulate ER␣ or LH␤ gene expression in pituitary cells (unpublished data). Moreover, pulsatile GnRH treatment of pituitary cell aggregates (10 nm/1 min⅐h) increased ER␣ mRNA levels after 4 h of pulses (32) . We thus hypothesized that the previously observed actions of GnRH on ER␣ expression may result from the effects of functional cross-talk between GnRH and ER in the gonadotrope cells.
The purpose of the present study was to explore the possibility of involvement of multiple signal transduction pathways in regulating ER␣ transcriptional activity. As our in vitro and in vivo data suggested an interrelation between GnRH and pituitary ER␣ (32) (our unpublished data), we studied ER␣ transcriptional activity in response to GnRH to further identify the mechanisms by which the peptide could exert its effect on ER regulation. In this study we provide evidence that ER␣ can be transcriptionally activated in gonadotrope cells in an estrogen-independent manner. In view of the importance of PKC and MAPK in GnRH signaling, we were interested to determine whether the hormone-independent activation occurs through these PKC-and MAP-kinase dependent pathways.
Materials and Methods Animals
All animals studies were conducted in accordance with the Guidelines for Care and Use of Experimental Animals. Adult male Wistar rats (CERJ, Le Genest, France; 42-50 d of age) were housed under controlled light schedule of (14-h light, 10-h dark) and provided with rat pellets and water ad libitum. Anterior pituitaries were washed in medium 199 -0.3% BSA before cell dispersion.
Cell cultures and transfection
Pituitary cell monolayers. Anterior pituitary cells were obtained by trypsin dispersion from glands as previously described (32) . For transfection studies, dispersed cells were plated in six-well dishes at 1 ϫ 10 6 cells/ well in a humidified atmosphere of 5% CO 2 in MEM containing d-valine (Sigma, St. Louis, MO), 0.1 mg/ml kanamycin sulfate, 2.5 g/ml fungizone (Sigma), and 10% FCS (24) . After 3 d, cells were washed, incubated for 2 h in MEM-d-valine supplemented with 2% steroid free Ultroser (Biosepra SA, Cergy-St Christophe, France), and transfected as indicated.
␣T3-1 cells. The gonadotrope-derived clonal cell line expressing the ␣-subunit and containing GnRH receptors was provided by Dr. P. Mellon (33) . Cells were grown in DMEM in high glucose with l-glutamine and sodium pyruvate (Life Technologies, Inc., Gaithersburg, MD), 10% FBS, 0.1 mg/ml kanamycin sulfate, and 2.5 g/ml fungizone. Three days before transfection, cells (1-2 ϫ 10 5 cells) were plated on six-well plates.
Two hours before transfection, cells were washed, and medium was replaced by serum-free medium supplemented with 2% USF. For all studies cells were transfected with estrogen response element (ERE)-luciferase reporter genes (1 g/well) using Fugene-6 (Roche Molecular Biochemicals, Indianapolis, IN) according to manufacturer's instructions, washed, and treated with E2 (10 nm) or vehicle alone for 48 h. GnRH (Sigma) or des-Gly 10 -[d-Ala 6 ]LHRH ethylamide (Sigma) were applied for the last 8 h before harvesting the cells. All transfection experiments were performed in triplicate. After treatments, cells were washed and lysed by thawing in 150 l lysis buffer (Promega Corp., Charbonnières, France). Luciferase activity was determined with reagents from Promega Corp. according to the manufacturer using a luminometer (ML 3000, Dynatech Corp., Chantilly, VA). Protein concentrations in cell lysates were determined using the colorimetric protein assay system (Bio-Rad Laboratories, Inc., Richmond, CA). Results were expressed as luciferase activity normalized per 100 g proteins.
Data analyses
Results are expressed as the mean Ϯ sem of 3-10 experiments, each performed in triplicate. Statistical analysis were carried out by one-or two-way ANOVA. Significant differences between treatment groups were determined by Fisher's test. Statistical significance was inferred at P Ͻ 0.05.
Results

Steroid-independent trans-activation of ER␣ by GnRH in the gonadotrope-derived ␣T3-1 cells
We assessed whether the peptide GnRH that elicits physiological variation in pituitary ER␣ mRNA levels (32) could also regulate ER␣-dependent transcription from an ERE reporter gene. To examine the transcriptional activity of the ER␣ in response to GnRH, ␣T3-1, a gonadotrope-derived cell line (33) was chosen. Cells were transfected with an EREluciferase reporter construct (ERE-SV-LUC) and treated with ethanol vehicle (control) or E2 (10 nm) for 48 h. GnRH (100 nm) was added for the last 8 h before harvesting. Luciferase activity was normalized for protein content. E2 treatment significantly stimulated ERE-SV-LUC activity by 2.3-fold vs. untreated control ( Fig. 1 ; P Ͻ 0.01 vs. control; n ϭ 10). Neither GnRH nor E2 enhanced transcription from the control reporter plasmid lacking the ERE sequence (SV-LUC; data not shown). GnRH alone induced a stimulation of reporter gene activity (4.5-fold vs. untreated control; n ϭ 10), which was significantly more potent than that seen with E2 alone (ϳ2-fold; P Ͻ 0.05 vs. E2; n ϭ 10). Treatment of the cells with E2 for 48 h coupled with GnRH administration during the last 8 h resulted in an 8-fold increase vs. the untreated control value ( Fig. 1 ; n ϭ 10; P Ͻ 0.001 vs. GnRH alone). In addition, ANOVA showed an additive effect between E2 and GnRH. Similar results were obtained in ␣T3-1 cells transfected with a ERE-tk-LUC reporter vector (data not shown), demonstrating that the enhancement of transcription by GnRH was not promoter dependent.
Dose-response studies of the stimulation of reporter activity in ␣T3-1 cells transiently transfected with ERE-SV-LUC showed a dose-dependent increase in luciferase activity in response to both GnRH and GnRH/E2 (Fig. 2) . GnRH stimulated luciferase activity at the smaller dose tested (1 nm), with maximal stimulation occurring at 100 nm. No further increase was observed with 1 m GnRH (not shown). A similar pattern was seen for GnRH/E2 cotreatment (Fig. 2) . In both cases the effects were linear in the tested range (r ϭ 0.955 for GnRH alone or GnRH/E2, respectively; n ϭ 3). Stimulation of ␣T3-1 cells with GnRH/E2 clearly resulted in an additive effect on the stimulation of LUC activity, as the calculated sum of the individual inductions was similar to the measured inductions of E2/GnRH cotreatment at three doses (sum calculated of individual inductions by E2 and GnRH vs. measured induction by E2/GnRH cotreatment, 2.9 vs. 4.1, 4.7 vs. 6.9, and 7.8 vs. 10.6, respectively for 1, 10, and 100 nm GnRH; n ϭ 3). A dose-response study with the GnRH agonist, des-Gly 10 -[d-Ala 6 ]LHRH ethylamide, showed a similar pattern (not shown). As E2 was used at a saturating concentration, those results suggest that E2 and GnRH mechanisms of ER␣ activation are different.
Inhibition of ER␣-mediated transcription by antiestrogen or GnRH antagonist in ␣T3-1 cells
To determine the role of ER␣ in GnRH-mediated activation, the pure antiestrogen, ICI 182,780, was employed. In ]LRF (luteinizing releasing hormone) (Dr. Rivier) was added to ␣T3-1 cells 60 min before GnRH. The ability of GnRH to trans-activate ER␣ was abolished at the control level by the presence of GnRH antagonist (Fig. 3B ), indicating that activation by GnRH is mediated by its own receptor. In addition, the stimulatory effect of GnRH/E2 was reduced by 70% at approximately the level of estrogen-treated cells. Thus, the data show that transcriptional effects were dependent on both ER␣ and GnRH-R.
Effect of GnRH on ER␣ trans-activation in the primary pituitary cells
To determine whether the ligand-independent activation pathway also exists in pituitary gland, primary pituitary cell cultures were transiently transfected with an ERE-luciferase reporter construct (ERE-SV-LUC) in steroid-free, phenol redfree medium. After transfection, cells were treated with either ethanol vehicle or E2 (10 nm) for 48 h. GnRH (100 nm) was added for the final 8 h before harvesting the cells. Figure  4 shows that E2 treatment resulted in a weak, but significant, increase in reporter luciferase activity (1.64 Ϯ 0.10-fold vs. control; n ϭ 4; P Ͻ 0.05). Treatment with 100 nm GnRH alone caused a slight stimulation of reporter gene activity over the 
FIG. 2. GnRH dose-response study of ER␣ trans-activation in ␣T3-1
Cells. The gonadotrope cell line was transiently transfected with ERE-SV-LUC plasmid and thereafter treated with or without E2 (10 nM) as described in Fig. 1 before the addition of increasing concentrations of GnRH (1-100 nM) for the last 8 h. Luciferase activity was normalized for protein content. Results are expressed as the fold induction over the untreated control value and are the mean Ϯ SEM of three independent experiments. In absence of E2, columns with different superscripts differ significantly (P Ͻ 0.05, by Fisher's test). In the presence of E2, columns with different superscripts differ significantly (P Ͻ 0.05, by Fisher's test).
control level (1.33 Ϯ 0.15-fold vs. control; n ϭ 4); however, this variation was not statistically significant. Interestingly, GnRH significantly increased ER␣ trans-activation when combined with E2. The ER␣ trans-activation by the combination of GnRH/E2 was enhanced approximately 3-fold vs. the unstimulated control value (n ϭ 4; P Ͻ 0.0001). The increase was 1.8-fold over that seen with E2 alone (n ϭ 4; P Ͻ 0.005). Moreover, a significant interaction between E2 and GnRH was observed on ER trans-activation (by two-ANOVA, P Ͻ 0.0001). In addition, the ability of GnRH or GnRH/E2 to trans-activate the ER␣ was blocked by ICI 182,780 (100 nm; Fig. 4) , suggesting that the transcriptional effects of GnRH were ER␣ dependent. Taken together, these results demonstrate that ER␣ can be activated in primary pituitary cells by GnRH in addition to estrogens.
GnRH-dependent activation of ER␣ involves PKC and MAPK pathways
As it is well known that PKC is one of the intracellular effectors of GnRH-R, we investigated the potential role of the PKC pathway in ER-mediated transcription in response to GnRH by using an inhibitor of PKC. Bisindolylmaleimide (GF109203X), a PKC inhibitor (inhibitor of PKC␣, -␤ 1 , -␤ II , -␥, -␦, and -⌺ isozymes), was tested. ␣T3 cells were transfected with ERE-SV-LUC and treated for 48 h with E2 (10 nm) or vehicle. The cells were pretreated for 60 min with or without GF109203X (10 m) before treatment with GnRH (100 nm). As shown in Fig. 5A , GF109203X caused a complete inhibition of ER␣ trans-activation in response to GnRH, whereas the ability of GnRH/E2 to enhance the ER trans-activation was partly reduced, indicating that this pathway is involved in the GnRH-induced enhancement of ER␣ transcriptional activity.
As GnRH has been reported to be capable of activating MAPK in pituitary organ culture and in the ␣T3-1 gonadotroph cell line via PKC (10, 12), we investigated whether MAPK could play a role in the cross-talk between GnRH and ER␣. We tested the effect of PD98059, a specific MAPKK inhibitor, on GnRH-mediated ER␣ trans-activation in the ␣T3-1 gonadotroph cell line. Cells were transfected with ERE-SV-LUC reporter and then treated with ethanol or E2 (10 nm). PD98059 (50 m) was introduced 1 h before adding GnRH (100 nm). Figure 5B shows that the MAPKK inhibitor induced a 60% inhibition of GnRH-mediated activation of the ERE reporter (n ϭ 2). The GnRH/E2 activation of ERE reporter was reduced 65% by PD98059. This remaining activity could correspond to E2-dependent activation. These results suggest that ER␣ activation by GnRH proceeds via a MAPK dependent-pathway.
Discussion
Estradiol is well known to be an important physiological regulator of the pituitary gland secretory activity. Although other proteins are involved, the receptor is the limiting factor that dictates the magnitude of the steroid response, with the primary endocrine regulator being the ligand itself. However, an increasing number of alternate regulatory mechanisms have been described for a number of members of this superfamily (14 -23) . Little is known about mechanisms governing the physiological regulation of ER␣ in the pituitary gland. Several arguments support the hypothesis that GnRH could affect the transcriptional activation function of the ER␣ in gonadotrope cells. Singh and Muldoon (31) have shown that exposure to GnRH significantly increased nuclear E2 binding. Weisenberg et al. (30) reported that the number of pituitary ER-binding sites is dependent on trophic factors ]LRF; GnRH anta) for 1 h before the addition of GnRH. The peptide GnRH (100 nM) was added for the last 8 h. Luciferase activity was normalized for protein content. Results, expressed as the fold induction over untreated control, are representative of two independent experiments conducted in triplicate. They are expressed as the mean Ϯ range.
from the hypothalamus. In a previous study we have demonstrated that GnRH pulsatile administration enhances ER␣ mRNA expression in rat pituitary cells (32) . In this report we have further shown that GnRH activates the estrogen signaling pathway in the pituitary gland.
Ligand-independent activation of the ER␣ is indeed observed in gonadotrope-derived cell lines (␣T3-1 cells) transiently transfected with estrogen-inducible reporter constructs (ERE-SV-LUC and ERE-tk-LUC) and treated with GnRH. The magnitude of the ligand-independent activation of the ER␣ by GnRH that we observed was 2-fold higher than that seen with E2. The stimulatory effect of GnRH on ER␣-mediated reporter gene transcription was enhanced in the presence of E2, resulting in an additive effect. The ability of GnRH to trans-activate the ER␣ in presence or absence of E2 was blocked both by a pure antiestrogen (ICI 182,780) and a GnRH antagonist. Thus, our results demonstrate that the expression of estrogen-responsive reporter genes may be stimulated by a peptide factor, GnRH, in the absence of E2 and in a manner dependent upon the presence of ER␣ and GnRH-R in gonadotrope-derived cell lines. The fact that addition of GnRH in the presence of a saturating dose of E2 results in a further and additive increase in reporter gene expression indicates that there are basic differences between the mechanisms of ligand-independent and ligand-dependent activation of ER␣, suggesting the involvement of two different pathways.
The ligand-independent trans-activation of ER␣ by GnRH was not detected in primary pituitary cells, probably due to the heterogeneity of the cell types present in the pituitary and the low amount of gonadotropes (10%) (35) . Thus, although the mechanisms of E2 action on gonadotropes are not well defined, it appears to modulate GnRH action by exerting coordinated effects at and distal to the GnRH receptor. We show that the effect of GnRH/E2 is completely blocked by ICI 182,780, indicating that the response is dependent upon a functional ER. These results imply cross-talk between the ER␣ and GnRH signal transduction pathways and a role for GnRH in E2 signaling in the gonadotropes.
GnRH binding triggers activation of the MAPK pathway through a mechanism involving PKC in primary rat pituitary cells as well as in the gonadotrope-derived ␣T3-1 cells (9, 11) . Given this evidence, we assessed the involvement of the PKC and MAPK signaling pathways in the cross-talk between GnRH-R and ER␣ in ␣T3-1 by treating cells with protein kinase inhibitors. The PKC inhibitor, GF109203X, completely blocked the reporter trans-activation resulting from GnRH action, whereas the combined action of GnRH/E2 was partly inhibited, suggesting the involvement of the PKC pathway. Although the PKA pathway does not appear to be involved in GnRH-mediated effect in ␣T3 cells (9, 11), we cannot totally exclude that with the concentration of GF109203X used in this study the PKA pathway is not also partly affected. Treatment with PD098059, which inhibits the MAPK pathway, decreased GnRH-or GnRH/E2-mediated activation of the ERE reporter by 60% and 65%, respectively. Thus, our data demonstrate that the effects of GnRH on ER␣ activation in gonadotrope cells are mediated by the PKC/ MAPK pathway.
To our knowledge, this is the first report on the modulation of ER␣ transcriptional activation by GnRH in gonadotrope cells, suggesting that a GnRH-triggered signaling cascade can result in E2-independent trans-activation of the ER␣. There are numerous findings of ligand-independent activation of mammalian ER␣ in transiently transfected cells as well as in vivo (14 -16) . Several studies have now shown that ER␣ is subject to phosphorylation and activation induced by various peptide growth factors [e.g. epidermal growth factor (EGF) (36) , TGF␣ (36) IGF-I (22) , and heregulin (18)], events that can subsequently initiate ERE-mediated gene expression. Functional analyses of ER␣ have shown that the two transcriptional activation functions, AF-1 and AF-2, are differentially activated by those factors; AF-1 is more responsive to EGF and TGF␣ signaling, and IGF-I preferentially targets AF-2 (36, 37) . Three serine residues Ser 104 , Ser 106 , and Ser 118 are the targets of the cyclin-dependent kinases and MAP kinases (for reviews, see Refs. 14 -16). More detailed studies have confirmed that phosphorylation of Ser 118 is required for full activity of AF-1 and is mediated via the Ras/MAPK pathway in EGF-stimulated cells (36, 38 -40) . Recent studies provide evidence that the cross-talk between EGF and IGF-I with ER␣ in MCF-7 breast cancer cells involves Akt (41) . A potential PKA phosphorylation site does exist within the ER at Ser 236 (20) . Phosphorylation of ER␣ by casein kinase II and pp90 rsk1 on Ser 167 in vitro has also been demonstrated (for review, see Ref. 14) . PKC has been reported to phosphorylate the receptor on residue Ser 122 (21) , whereas tyrosine 537 is phosphorylable by members of the Src family of tyrosine kinases in vitro (42, 43) . Although activation of the ER␣ has been shown to be associated with phosphorylation of the AF-1 and AF-2 domains, the precise roles of individual phosphorylation sites are not known.
The additive activity displayed by GnRH and E2 is not easily comprehensible. As it is known that the ER␣ can be phosphorylated on different residues, it could be postulated that the ER␣ hyperactivity observed in the presence of GnRH and E2 is due to hyperphosphorylation of the receptor protein. At this stage we do not know whether ER␣ is the direct target of the phosphorylation events induced by the PKC/ MAPK pathways. We cannot exclude that a coactivator, interacting with ER␣, functions in a MAPK-induced phosphorylation way. Such a hypothesis may help to explain the additive increase in reporter gene activity that is activated by addition of GnRH in the presence of a saturating concentration of E2.
The data presented here provide evidence that the transcription factor ER␣ may mediate some of the effects of the hypothalamic factor, GnRH, suggesting that the interaction between ER␣ and GnRH signaling could have important physiological consequences. Feedback regulation by E2 at the level of both the hypothalamus and the pituitary is of fundamental importance for controlling reproduction in females. One of E2's effects is to sensitize the pituitary to hypothalamic signals such as GnRH. Signaling cascades initiated by GnRH binding to its receptor may modulate the transcriptional activity of ER␣, ligand-occupied or not, and thereby increase the magnitude of target gene expression. Alternatively, it is possible that GnRH contributes to maintain moderate levels of ER␣ activity in gonadotropes when estrogen levels are low, as observed in males or in females during diestrus. Indeed, it is conceivable that cross-talk pathways may sensitize the ER␣ to suboptimal stimulation by low levels of estrogens and thereby promote biologically meaningful responses under conditions in which ligand stimulus alone would be unable to generate a significant signal. It is not known whether the target genes activated by ER␣ in response to GnRH or E2 are identical or whether there are genes preferentially or selectively regulated by one or the other pathway. Although ␣-subunit promoter activity is dramatically affected by estrogen, no high affinity ERE has been identified in this promoter (1, 44) . On the other hand, an ERE was identified in the rat LH␤ gene (1) . Identification of such a mechanism may be of critical importance in the understanding the involvement of ER␣ in gonadotropin gene transcription. Although it is clear that GnRH is essential for gonadotropin gene expression, the transcription factors that ultimately are targets of GnRH action remain unknown. The PKC/MAPK pathway activated by GnRH preferentially stimulates ␣-subunit gene transcription by phosphorylation of the Ets family transcription factors, whereas induction of the LH␤ gene is dependent on PKC and calcium influx (45) . Recent studies have identified key factors involved in LH␤ gonadotropin gene transcription: the nuclear receptor SF-1, the bicoid-related homeoprotein Ptxl (Pitxl), and the immediate-early egr-1 gene (13) . A marked increase in gonadotropin mRNA levels has been observed in ER␣ genedisrupted female mice (46), consistent with previously described transcriptional suppression of gonadotropin subunit gene expression in response to sustained administration of E2 in wild-type mice. These results provide genetic evidence that ER␣ plays a critical role in gonadotropin gene transcription.
In summary, it appears that the mechanisms regulating pituitary ER␣ action are certainly complex. The data presented here extend previous observations regarding the regulation of pituitary ER␣ and show for the first time that rat pituitary ER␣ activity could be under hypothalamic control. Our data demonstrate that the rat ER␣ can be activated in the absence of estrogen through an alternate signaling pathway involving the GnRH receptor. This activation is dependent upon the presence of ER␣ and GnRH-R and mainly occurs via PKC and MAPK pathways. In addition, the mechanism of ER␣ activation by GnRH could differ from that used by E2. Cross-talk between the GnRH signal transduction system and ER␣ in gonadotrope cells may represent an important modulating mechanism for the estrogen responsiveness of gonadotrope cells.
